{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreianhyhhdk47us5jnzzciotusq5c36eavyoww7hrskj37foy6mhmeq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mp4go3hbjdf2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiguhdlyb7lrcskpedrpzxofqm76tyfalyncdgsuzzprpo6x2mjv2q"
    },
    "mimeType": "image/jpeg",
    "size": 644957
  },
  "path": "/news/2026-06-car-cell-therapy-year-remissions.html",
  "publishedAt": "2026-06-25T07:40:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy developed by Carl June, MD, that would go on to become the first such treatment approved by the FDA—were still alive without a lymphoma relapse, according to long-term follow-up data published in New England Journal of Medicine by researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.",
  "title": "CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients"
}